Introduction {#section1-1758835919849753}
============

The poly (ADP-ribose) polymerase (PARP) inhibitor olaparib (Lynparza™) was the first personalized treatment for patients with high-grade serous ovarian cancer, initially receiving regulatory approval in Europe for the treatment of those patients with a germline or somatic *BRCA1* or *BRCA2* mutation (BRCAm).^[@bibr1-1758835919849753]^

The activity of PARP inhibitors is based on the concept of synthetic lethality, where an underlying homologous recombination repair deficiency (HRD) in tumour cells makes the cells highly susceptible to PARP inhibition.^[@bibr2-1758835919849753]^ PARP inhibitors bind to and trap PARP1 and PARP2 on DNA at the sites of single-strand breaks, which results in the generation of a double-strand breaks. In cancer cells with HRD, double-strand DNA breaks are repaired by error-prone pathways (i.e. nonhomologous end joining), ultimately leading to cell death.^[@bibr2-1758835919849753][@bibr3-1758835919849753][@bibr4-1758835919849753]--[@bibr5-1758835919849753]^

Indeed, the mechanisms of action of PARP inhibitors are distinct from other targeted agents where drugs are designed to target specific driver mutations (oncogenes) or products thereof (such as tyrosine kinase inhibitors that directly inhibit mutated, constitutively activated tyrosine kinases).^[@bibr6-1758835919849753]^ In such instances, physicians can select for patients who are most likely to respond by directly screening for the genetic aberration synonymous with the mechanism of action (e.g. osimertinib treatment for patients with an EGFR T790M mutation).^[@bibr7-1758835919849753]^ In contrast, the antitumour effects of olaparib and other PARP inhibitors are not dependent on a direct interaction with a mutated gene/protein, but rather on an underlying defect in the DNA damage repair mechanism of cancer cells.

Platinum sensitivity and high-grade histology predict patients with homologous recombination repair deficiency {#section2-1758835919849753}
==============================================================================================================

HRD is a key determinant of platinum sensitivity in high-grade serous ovarian cancer,^[@bibr8-1758835919849753]^ and sensitivity to platinum agents is reported to correlate with sensitivity to olaparib.^[@bibr9-1758835919849753]^

The most profound deficit in the homologous recombination repair (HRR) pathway is seen in tumours with a BRCAm. Many of the preclinical studies undertaken during the development of PARP inhibitors targeted cells or murine tumour models deficient in BRCA as a marker of HRD.^[@bibr10-1758835919849753][@bibr11-1758835919849753]--[@bibr12-1758835919849753]^ However, clinical studies have demonstrated that sensitivity to PARP inhibitors occurs in tumours beyond those harbouring a BRCAm.^[@bibr5-1758835919849753],[@bibr13-1758835919849753],[@bibr14-1758835919849753]^ Until recently, hereditary epithelial ovarian cancer was thought to be almost exclusively the result of mutations in the *BRCA1* and *BRCA2* genes, with a minimal proportion resulting from DNA mismatch repair gene mutations.^[@bibr15-1758835919849753]^ BRCAm, germline or somatic, have been reported to occur in up to 18--25% of patients with newly diagnosed serous ovarian cancer.^[@bibr16-1758835919849753],[@bibr17-1758835919849753]^ In addition to BRCAm, the HRR pathway may be compromised by other mechanisms, examples of which include loss-of-function mutations in other HRR genes, epigenetic inactivation of *BRCA1* or methylation of *RAD51C* promoters.^[@bibr18-1758835919849753],[@bibr19-1758835919849753]^ Further investigation of the homologous recombination repair pathway in ovarian cancers has highlighted multiple other protein cofactors that are necessary for successful HRR, including TP53, ATM, MRE11, RAD51, H2AX, PALB2, RPA, BRIP1, BARD1, RAD52 and proteins of the Fanconi anaemia pathway, in addition to potentially unknown molecular targets.^[@bibr15-1758835919849753],[@bibr20-1758835919849753][@bibr21-1758835919849753][@bibr22-1758835919849753]--[@bibr23-1758835919849753]^ Data from The Cancer Genome Atlas suggest that approximately 50% of high-grade serous ovarian cancers (the most common histologic subtype) have a deficiency in HRR.^[@bibr23-1758835919849753]^

The relationship between sensitivity to PARP inhibitors and DNA repair deficiency is therefore likely to be more akin to a continuous than a discrete variable; for example, patients with a BRCAm are highly sensitive to PARP inhibition, but lack of a BRCAm does not preclude sensitivity to olaparib. As such, PARP inhibitors have the potential to be beneficial in a much wider proportion of ovarian-cancer patients than was originally proposed.

Olaparib for the treatment of platinum-sensitive relapsed ovarian cancer {#section3-1758835919849753}
========================================================================

Olaparib (Lynparza capsule formulation) received approval based on the results from Study 19 \[ClinicalTrials.gov identifier: NCT00753545\]. Study 19 was a randomized, placebo-controlled, phase II trial enrolling 265 patients who were clinically enriched for markers associated with a response to PARP-inhibitor treatment \[i.e. patients with high-grade serous platinum-sensitive relapsed (PSR) ovarian cancer who had received at least two platinum-based chemotherapy regimens and were in complete or partial response to their most recent regimen\]. Patients were randomized to olaparib maintenance treatment \[capsules; 400 mg twice daily (b.i.d.)\] or matching placebo. Median follow up for the primary analysis of progression-free survival (PFS) was 5.6 months in Study 19 and no further tumour assessments were performed following the primary data cut-off (DCO). Olaparib treatment improved PFS in Study 19 in the overall population \[hazard ratio (HR) 0.35, 95% confidence interval (CI) 0.25--0.49; *p* \< 0.0001 for olaparib *versus* placebo\]. A planned, retrospective analysis of BRCAm status was performed and information was obtained for 96% of the overall population. In the BRCAm population, the benefit of olaparib *versus* placebo was even greater (HR 0.18, 95% CI 0.10--0.31; *p *\< 0.0001) than in the non-BRCAm population (HR 0.54, 95% CI 0.34--0.85; *p *= 0.0075;^[@bibr24-1758835919849753],[@bibr25-1758835919849753]^ [Table 1](#table1-1758835919849753){ref-type="table"}).

###### 

PFS (investigator assessed), TFST, TSST and OS in the Study 19 trial of olaparib-capsule maintenance treatment.

![](10.1177_1758835919849753-table1)

  ------------------------------------------------------------------------------------------------------
                                               Median, months   HR (95% CI)   *p* value      
  -------------------------------------------- ---------------- ------------- -------------- -----------
  PFS,\                                        8.4              4.8           0.35\          \<0.0001
  overall population\                                                         (0.25--0.49)   
  (58% maturity)^[@bibr24-1758835919849753]^                                                 

  PFS BRCAm population)\                       11.2             4.3           0.18\          \<0.0001
  (53% maturity)^[@bibr25-1758835919849753]^                                  (0.10--0.31)   

  TFST,\                                       13.3             6.7           0.39\          \<0.00001
  overall population\                                                         (0.30--0.52)   
  (87% maturity)^[@bibr26-1758835919849753]^                                                 

  TFST,\                                       15.6             6.2           0.33\          \<0.00001
  BRCAm population\                                                           (0.22--0.49)   
  (84% maturity)^[@bibr26-1758835919849753]^                                                 

  TSST,\                                       19.1             14.8          0.53\          \<0.00001
  overall population\                                                         (0.40--0.69)   
  (85% maturity)^[@bibr26-1758835919849753]^                                                 

  TSST,\                                       21.4             15.3          0.43\          \<0.00003
  BRCAm population\                                                           (0.29--0.64)   
  (80% maturity)^[@bibr26-1758835919849753]^                                                 

  OS,\                                         29.8             27.8          0.73\          0.021
  overall population\                                                         (0.55--0.95)   
  (79% maturity)^[@bibr26-1758835919849753]^                                                 

  OS,\                                         34.9             30.2          0.62\          0.021
  BRCAm population\                                                           (0.42--0.93)   
  (73% maturity)^[@bibr26-1758835919849753]^                                                 
  ------------------------------------------------------------------------------------------------------

Blinded, independent, central review assessment of PFS endpoints supported the investigator-assessed primary analysis of PFS.

BRCAm, BRCA mutation; CI, confidence interval; HR, hazard ratio; OS, overall survival; PFS, progression-free survival; TFST, time to first subsequent treatment; TSST, time to second subsequent treatment.

Novel intermediate endpoints between PFS and overall survival (OS) have been included in ovarian cancer clinical trials. One of these is the time from randomization to first subsequent therapy or death (TFST), which considers any differences between the time of radiological progression and the start of the next line of treatment, as well as providing important information for the patient, who is interested in knowing when they are likely to receive their next line of chemotherapy. In the case of Study 19, TFST has also provided significantly more mature efficacy information beyond the initial PFS DCO analysis, which occurred when the median follow up was only 5.6 months, with significant data immaturity in the olaparib arm, compared with a median follow up of 77.4 months for TFST. TFST in Study 19 was shown to be significantly longer in the olaparib arm than for placebo-treated patients in the overall study population, BRCAm and non-BRCAm subgroups ([Figure 1](#fig1-1758835919849753){ref-type="fig"}; [Table 1](#table1-1758835919849753){ref-type="table"}).

![Study 19: TFST and TSST in all patients and according to BRCAm status.\
(a) TFST in the overall study population; (b) TFST in the BRCAm subgroup; (c) TFST in the non-BRCAm subgroup; (d) TSST in the overall study population; (e) TSST in the BRCAm subgroup; and (f) TSST in the non-BRCAm subgroup.\
BRCAm, BRCA mutation; BRCAwt, BRCA wild type; CI, confidence interval; HR, hazard ratio; TFST, time to first subsequent therapy; TSST, time to second subsequent therapy.\
Figure reproduced from Friedlander et al.^[@bibr26-1758835919849753]^ (<https://creativecommons.org/licenses/by/4.0/>).](10.1177_1758835919849753-fig1){#fig1-1758835919849753}

Although OS remains an accepted and important clinical trial endpoint, it is becoming increasingly difficult to detect an OS benefit for investigational treatments because of confounding factors such as crossover to the experimental drug, the use of multiple lines of chemotherapy and investigational treatments following disease progression.^[@bibr27-1758835919849753]^ As such, observation of significant improvement in PFS can be supported by other intermediate endpoints between PFS and OS, which also have value in indicating whether investigational treatments can provide extended benefit, beyond initial disease progression. Such intermediate endpoints include the time from randomization to second subsequent therapy or death (TSST), and time from randomization to second disease progression or death (PFS2), which are being introduced into oncology clinical trials.^[@bibr28-1758835919849753],[@bibr29-1758835919849753]^

Consistent with the PFS and TFST benefit observed in patients receiving olaparib, TSST was also significantly longer in the olaparib arm than the placebo arm in the overall study population, BRCAm and non-BRCAm subgroups ([Figure 1](#fig1-1758835919849753){ref-type="fig"}; [Table 1](#table1-1758835919849753){ref-type="table"}), demonstrating a clinically meaningful increase in time between chemotherapy regimens, while also providing evidence of a sustained benefit of olaparib treatment in both BRCAm and non-BRCAm populations after long-term follow up.^[@bibr26-1758835919849753],[@bibr30-1758835919849753]^

After a median follow up of 6.5 years (79% data maturity), there was a clinically significant improvement in OS in the overall population of Study 19 (HR 0.73, 95% CI 0.55--0.95; nominal *p *= 0.021) and in patients with a BRCAm (HR 0.62, 95% CI 0.42--0.93; *p *= 0.021; [Figure 2](#fig2-1758835919849753){ref-type="fig"}).^[@bibr26-1758835919849753]^ Although the criterion for statistical significance (*p *\< 0.0095) was not reached for OS because of the alpha spending approach used during interim analyses of the trial, these data demonstrate continued treatment benefit. A separation in favour of olaparib treatment was seen in the Kaplan--Meier (KM) curves for the overall study population and the BRCAm subgroup as follow-up duration increased ([Figure 2](#fig2-1758835919849753){ref-type="fig"}). The separation of the KM curves became more apparent after 36 months of follow up, reflecting the long-term benefit derived for olaparib-treated patients.^[@bibr26-1758835919849753]^ Furthermore, the HRs reported are unadjusted for patient crossover, and 13% of placebo-receiving patients received postdiscontinuation PARP-inhibitor treatment in other clinical trials, whereas no patients in the olaparib arm received retreatment with olaparib or any other subsequent PARP-inhibitor treatment.^[@bibr26-1758835919849753]^

![Study 19: final overall survival in all patients and according to BRCAm status.\
(a) OS in overall study population; (b) OS in BRCAm subgroup; (c) OS in non-BRCAm subgroup.\
BRCAm, BRCA mutation; CI, confidence interval; HR, hazard ratio; OS, overall survival.\
Figure reproduced from Friedlander et al.^[@bibr26-1758835919849753]^ (<https://creativecommons.org/licenses/by/4.0/>).](10.1177_1758835919849753-fig2){#fig2-1758835919849753}

The long-term exposure seen in Study 19 is unprecedented for therapy in recurrent ovarian cancer. Eighteen patients in the olaparib arm remained on study treatment for at least 5 years (13%), of whom 11 had a BRCAm and seven were non-BRCAm; in the placebo arm, only one patient (1%) stayed on treatment for at least 5 years.^[@bibr26-1758835919849753]^ Consistent across BRCAm and non-BRCAm subgroups, approximately 10% of patients experienced a durable benefit from olaparib maintenance monotherapy for at least 6 years.^[@bibr26-1758835919849753]^ Over a third of patients who had received olaparib for at least 6 years did not harbour a BRCAm. Of the 15 patients who received olaparib for at least 6 years, nine had a BRCAm, three of whom had a somatic BRCAm, and a slight preponderance of *BRCA2* mutations was observed (*BRCA2*m, *n* = 5; *BRCA1*m, *n* = 3; *BRCA1*m or *BRCA2*m, *n* = 1); five patients were non-BRCAm, one of whom was found to have a *RAD51B* mutation, the HRR status (determined by Foundation Medicine T5 panel test)^[@bibr31-1758835919849753],[@bibr32-1758835919849753]^ was unknown for two patients, one of whom was HRD positive (determined by Myriad myChoice® HRD (Myriad Genetics, Inc. UT, USA) HRR deficiency test),^[@bibr31-1758835919849753],[@bibr33-1758835919849753]^ and two patients had no HRR mutations, one of whom was HRD negative.^[@bibr13-1758835919849753]^ One patient, who was germline BRCA wild type, had no available tumour test results ([Figure 3](#fig3-1758835919849753){ref-type="fig"}).^[@bibr13-1758835919849753]^ These data demonstrate that there are patients beyond those with a BRCAm who derive a long-term benefit from PARP-inhibitor treatment in line with the US Food and Drug Administration (FDA) and the updated European indication for olaparib (all PSR ovarian cancer patients who are in complete or partial response to their last platinum treatment).^[@bibr34-1758835919849753]^

![Biomarker characterization in patients receiving olaparib for ⩾6 years in Study 19.\
^\*^This patient was found to have a RAD51B mutation.\
^\$^Two of five BRCAwt patients had no available Myriad HRD score result.\
BRCAm, BRCA mutation; BRCAwt, BRCA wild type; gBRCAwt, germline BRCA wild type; HRD, homologous recombination repair deficiency; HRRm, homologous recombination repair mutation; HRRwt, HRR wild type; sBRCAm, somatic BRCA mutation; tBRCA, tumour BRCA.](10.1177_1758835919849753-fig3){#fig3-1758835919849753}

The full dose for the originally approved olaparib formulation was 400 mg b.i.d. administered as eight 50 mg capsules;^[@bibr35-1758835919849753],[@bibr36-1758835919849753]^ because of the high administration burden of the capsules, an alternative tablet formulation was developed. The capsule and tablet formulations are not bioequivalent, therefore an adaptive study, Study 24 \[ClinicalTrials.gov identifier: NCT00777582\] enrolling patients with advanced solid tumours, including patients with BRCAm ovarian and breast cancer, was performed to determine the optimal dose of the tablet formulation for use in phase III trials. This study determined that the olaparib 300 mg b.i.d. (2 × 150 mg) tablet formulation matched or exceeded the exposure of 400 mg b.i.d. capsules; the 300 mg b.i.d. tablet regimen was also shown to be non-inferior to 400 mg b.i.d. capsules in terms of tumour shrinkage,^[@bibr37-1758835919849753]^ which led to 300 mg b.i.d. tablets being assessed in phase III trials of olaparib.

The SOLO2 \[ClinicalTrials.gov identifier: NCT01874353\] study of olaparib was designed to evaluate the tablet formulation (300 mg b.i.d.) and to confirm the efficacy of olaparib in a phase III trial of patients with BRCAm, PSR ovarian cancer who were in complete or partial response to their most recent platinum-based regimen. It confirmed the efficacy of olaparib in this patient population with a significant improvement in both the investigator-assessed (primary endpoint) and blinded, independent central review (BICR; sensitivity analysis) PFS following olaparib treatment *versus* placebo (investigator-assessed median PFS: 19.1 *versus* 5.5 months, respectively; HR 0.30, 95% CI 0.22--0.41; *p *\< 0.0001; [Table 2](#table2-1758835919849753){ref-type="table"}; BICR median PFS: 30.2 *versus* 5.5 months; HR 0.25, 95% CI 0.18--0.35; *p *\< 0.0001).^[@bibr38-1758835919849753]^ Of note, the BICR median PFS following olaparib treatment was over 11 months longer than the investigator-assessed median PFS. Differences in median PFS between investigator- and BICR-assessed PFS have also been observed in clinical trials of the PARP inhibitors niraparib and rucaparib in patients with ovarian cancer. When only local review shows progression, no further assessments are performed, and patients are censored in the BICR analysis. BICR medians are shown to be exaggerated if there is a positive correlation between BICR and local evaluation PFS times, especially when patients are assessed many times prior to progression. When efficacy is substantial, it can lead to exaggeration of the difference in medians between arms. However, the HR is much less susceptible to bias and is therefore a more reliable indicator of the true treatment effect and the most valid measure to describe the benefit of a PFS analysis.^[@bibr39-1758835919849753]^

###### 

PFS (investigator assessed), TFST, PFS2 and TSST in the SOLO2 trial of olaparib tablet maintenance treatment in patients with a BRCAm^[@bibr38-1758835919849753]^.

![](10.1177_1758835919849753-table2)

  ------------------------------------------------------------------------------------------------------------------------
                                                                  Median, months   HR (95% CI)   *p* value      
  --------------------------------------------------------------- ---------------- ------------- -------------- ----------
  PFS\                                                            19.1             5.5           0.30\          \<0.0001
  (63% maturity)                                                                                 (0.22--0.41)   

  TFST\                                                           27.9             7.1           0.28\          \<0.0001
  (58% maturity)                                                                                 (0.21--0.38)   

  PFS2^[\*](#table-fn4-1758835919849753){ref-type="table-fn"}^\   NR               18.4          0.50\          \<0.0002
  (40% maturity)                                                                                 (0.34--0.72)   

  TSST^[\*](#table-fn4-1758835919849753){ref-type="table-fn"}^\   NR               18.2          0.37\          0.0001
  (43% maturity)                                                                                 (0.26--0.53)   
  ------------------------------------------------------------------------------------------------------------------------

Blinded, independent, central review assessment of PFS endpoints supported the investigator-assessed primary analysis of PFS.

The analysis of TSST included more events than did analysis of PFS2 (128 *versus* 119) because at the time of data cut-off, some patients who had received a second subsequent therapy were not yet classed as having investigator-assessed disease progression following their first subsequent therapy.

BRCAm, BRCA mutation; CI, confidence interval; HR, hazard ratio; NR, not reached; PFS, progression-free survival; PFS2, time to second progression or death; TFST, time to first subsequent treatment; TSST, time to second subsequent treatment.

In the SOLO2 trial, TFST, PFS2 and TSST were included as prospective secondary endpoints rather than exploratory endpoints (TFST and TSST) as in Study 19. In SOLO2, at the time of the primary PFS analysis, median TFST was 27.9 months (95% CI 22.6--not calculable) in the olaparib group *versus* 7.1 months (6.3--8.3) for placebo; median PFS2 was not reached in patients receiving olaparib (24.1--not calculable) and was 18.4 months (15.4--22.8) in the placebo group; and median TSST in the olaparib group was not reached (95% CIs not calculable) and was 18.2 months (15.0--20.5) in the placebo group;^[@bibr38-1758835919849753]^ these data further demonstrated the prolonged efficacy of olaparib in patients with ovarian cancer beyond completion of their treatment with olaparib. OS data for SOLO2 are not yet mature.^[@bibr38-1758835919849753]^

Study 19 allowed patients to continue to receive their randomized treatment beyond Response Evaluation Criteria in Solid Tumours (RECIST) progression ([Table 3](#table3-1758835919849753){ref-type="table"}). Although the majority of patients who had progressed at the time of DCO discontinued their olaparib treatment within 2 weeks of their progression date, a proportion of patients continued with olaparib treatment for \>2 weeks after progression. Similarly, in SOLO2, patients could continue with treatment beyond their RECIST progression. Of interest in Study 19, seven (41%) patients continued treatment with olaparib for more than 3 months following disease progression \[*versus* four (24%) on placebo\] and in SOLO2, 20 (48%) women continued with olaparib for more than 3 months following their disease progression \[*versus* three (13%) on placebo\], with five (12%) patients continuing olaparib treatment for more than 12 months following progression \[*versus* one (4%) on placebo; AstraZeneca, Cambridge, UK, 2019; [Table 3](#table3-1758835919849753){ref-type="table"}\]. Although these exploratory data should be interpreted with caution, they highlight that patients are tolerating olaparib treatment well and are the first data to demonstrate that the investigators believe patients are still deriving benefit from PARP-inhibitor treatment, even in the context of progressive disease.

###### 

Patients who continued randomized treatment for more than 2 weeks following RECIST disease progression in Study 19 and SOLO2.

![](10.1177_1758835919849753-table3)

                                                                                      Olaparib    Placebo
  ----------------------------------------------------------------------------------- ----------- -----------
  **Study 19 full analysis set, *n***                                                 136         128
  Patients, who continued treatment \>2 weeks following RECIST progression, *n* (%)   17 (12.5)   17 (13.3)
  Time to treatment discontinuation following RECIST progression date, *n* (%)                    
   ⩽3 months                                                                          10 (58.8)   13 (76.5)
   \>3--⩽6 months                                                                     2 (11.8)    2 (11.8)
   \>6--⩽12 months                                                                    3 (17.6)    1 (5.9)
   \>12 months                                                                        2 (11.8)    1 (5.9)
  **SOLO2 full analysis set, *n***                                                    195         99
  Patients who continued treatment \>2 weeks following RECIST progression, *n* (%)    42 (21.5)   23 (23.2)
  Time to treatment discontinuation following RECIST progression date, *n* (%)                    
   ⩽3 months                                                                          22 (52.4)   20 (87.0)
   \>3--⩽6 months                                                                     7 (16.7)    1 (4.3)
   \>6--⩽12 months                                                                    8 (19.0)    1 (4.3)
   \>12 months                                                                        5 (11.9)    1 (4.3)

For SOLO2, the progression date is based on that determined by investigator assessment.

RECIST, Response Evaluation Criteria in Solid Tumours.

The median PFS difference for patients with a BRCAm between the two olaparib trials \[11.2 *versus* 19.1 months for patients treated with olaparib in Study 19 (capsule formulation) *versus* SOLO2 (tablet formulation), as assessed by the investigator\] might be interpreted as a difference in the efficacy of the formulations; however, there are several other factors that could explain the observed variance. First, differences were observed for the median number of prior chemotherapies; patients in Study 19 had a median of three prior lines of chemotherapy and in SOLO2, patients had a median of two prior lines of chemotherapy (44% and 56% of patients receiving olaparib in Study 19 and SOLO2 had received two prior lines of chemotherapy, respectively). It is known that with each additional line of chemotherapy a patient with ovarian cancer receives, their PFS interval is reduced.^[@bibr40-1758835919849753]^ Therefore, patients in SOLO2 would be expected to perform better than those from Study 19. Secondly, the HRs observed for PFS indicate efficacy in both trials (0.18 and 0.30, respectively). It should also be noted that methodological bias can affect PFS data, including the median. As noted previously, the HR is currently the most valid measure to describe the benefit of a PFS analysis and is therefore a more reliable indicator of the true treatment effect.^[@bibr39-1758835919849753]^ Other factors that could contribute to the variance in PFS between the studies are the nonequivalent bioavailability of the two olaparib formulations,^[@bibr37-1758835919849753]^ and the data maturity for PFS events between the two trials, with the data from Study 19 being less mature than those from SOLO2 (53% and 63%, respectively).

The safety and tolerability of olaparib capsule and tablet formulations have been well document-ed.^[@bibr24-1758835919849753],[@bibr25-1758835919849753],[@bibr37-1758835919849753],[@bibr38-1758835919849753],[@bibr41-1758835919849753]^ The most common adverse events experienced following olaparib treatment are fatigue or gastrointestinal symptoms, or haematological side effects, which are mostly of low-grade severity (grade 1--2) and manageable with supportive treatment with or without dose modifications.^[@bibr25-1758835919849753],[@bibr38-1758835919849753]^ Importantly, in both Study 19 and SOLO2, olaparib maintenance therapy did not have a significant detrimental effect on health-related quality of life (HRQoL) compared with placebo.^[@bibr42-1758835919849753],[@bibr43-1758835919849753]^ SOLO2 was the first trial to report the impact of maintenance therapy with a PARP inhibitor on predefined HRQoL and patient-centred endpoints to help interpret the benefits of prolongation of PFS in the patient population. This is particularly important in maintenance therapy trials given that most patients do not have symptoms associated with ovarian cancer at randomization. In the prespecified primary HRQoL analysis for SOLO2, the mean change from baseline in the Functional Assessment of Cancer Therapy: Ovarian Cancer (FACT-O) Trial Outcome Index score during the first 12 months of the study did not significantly differ between olaparib and placebo groups.^[@bibr38-1758835919849753]^ Furthermore, secondary planned quality of life (QoL) analyses demonstrated a significantly longer quality-adjusted PFS (QAPFS; mean QAPFS 13.96 *versus* 7.28 months) and time without symptoms or toxicity (TWiST; 15.03 *versus* 7.70 months) in patients randomized to olaparib compared with placebo, respectively.^[@bibr44-1758835919849753]^ TWiST and QAPFS use validated measures and are well-developed methods of describing the duration of 'good QoL' in clinical trials for patients with a wide range of malignancies.^[@bibr45-1758835919849753][@bibr46-1758835919849753][@bibr47-1758835919849753]--[@bibr48-1758835919849753]^ These results support the primary outcome of SOLO2 and indicate that the significant prolongation of PFS with olaparib in this patient population was achieved with no appreciable detrimental effect on patients' QoL, supported by additional patient-centred benefits.^[@bibr44-1758835919849753]^

Several ongoing trials are evaluating olaparib (tablet formulation) in patients with ovarian cancer who do not have a BRCAm, including the phase IIIb trial OPINION \[ClinicalTrials.gov identifier: NCT03402841 (olaparib maintenance monotherapy in PSR non-germline BRCAm ovarian cancer patients)\], the phase III trials L-MOCA \[ClinicalTrials.gov identifier: NCT03534453; olaparib maintenance monotherapy in ovarian cancer patients after complete or partial response to platinum (a Chinese study)\] and OReO \[ClinicalTrials.gov identifier: NCT03106987 (olaparib retreatment in patients with or without a BRCAm)\], and the phase II LIGHT study \[ClinicalTrials.gov identifier: NCT02983799 (olaparib monotherapy treatment in ovarian cancer patients with different HRD tumour status)\].

Indications for PARP inhibitors in patients with recurrent ovarian cancer {#section4-1758835919849753}
=========================================================================

The initial approval of olaparib in December 2014 by the FDA was as monotherapy in patients with deleterious or suspected deleterious germ-line BRCAm (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy;^[@bibr49-1758835919849753]^ and by the European Medicines Agency (EMA) as monotherapy for the maintenance treatment of adult patients with PSR BRCAm (germline or somatic) high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial response) to platinum-based chemotherapy.^[@bibr50-1758835919849753]^ Although originally approved for BRCAm ovarian cancer patients only, the unprecedented long-term efficacy observed from Study 19 in both BRCAm and non-BRCAm patients, the phase III SOLO2 results and those observed from other PARP-inhibitor ovarian cancer trials, led to expanding the FDA label of olaparib (tablet formulation) in August 2017 to include the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy, irrespective of their BRCAm status and the number of prior lines of platinum-based chemotherapy received.^[@bibr35-1758835919849753]^ In May 2018, the EMA also updated the olaparib (tablet formulation) indication for use as a maintenance therapy for patients with PSR high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy, regardless of their BRCAm status.^[@bibr34-1758835919849753]^

Trials with two other PARP inhibitors, niraparib and rucaparib, have confirmed the efficacy of these drugs as maintenance therapy for patients with PSR ovarian cancer who are in response to their most recent platinum regimen, with or without a BRCAm. NOVA \[ClinicalTrials.gov identifier: NCT01847274\] was a phase III trial of niraparib maintenance treatment originally evaluated in platinum-sensitive ovarian cancer patients who have either a germline BRCAm or a tumour with high-grade histology and no germline BRCAm. Following a protocol amendment, the non-germline BRCAm cohort was hierarchically evaluated, first in a subgroup of patients positive for HRD (somatic BRCAm and HRD positive/BRCA wild type)^[@bibr51-1758835919849753]^ and then in all non-germline BRCAm patients.^[@bibr52-1758835919849753]^ Niraparib treatment improved PFS in all three cohorts *versus* placebo: in patients with a germline BRCAm (HR 0.27, 95% Cl 0.17--0.41), in the HRD-positive non-germline BRCAm cohort (HR 0.38, 95% CI 0.24--0.59) and in the overall non-germline BRCAm population (HR 0.45, 95% CI 0.34--0.61, *versus* placebo).^[@bibr14-1758835919849753]^ The results from the NOVA trial led to the FDA approval of niraparib (Zejula^®^) in March 2017 for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer in a complete or partial response to platinum-based chemotherapy;^[@bibr53-1758835919849753]^ and by the EMA in November 2017 as monotherapy for the maintenance treatment of adult patients with PSR high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.^[@bibr54-1758835919849753]^

Rucaparib has also been investigated as maintenance treatment in patients with PSR ovarian cancer in the phase III ARIEL3 study \[ClinicalTrials.gov identifier: NCT01968213\].^[@bibr55-1758835919849753]^ PFS was significantly improved across all primary analysis cohorts: in patients with a tumour BRCAm (HR 0.23, 95% CI 0.16--0.34), in the HRD-positive cohort (HR 0.32, 95% CI 0.24--0.42) that included BRCAm and BRCA wild-type patients with high loss of heterozygosity (LOH) scores^[@bibr56-1758835919849753]^ and in the overall population (HR 0.36, 95% CI 0.30--0.45, *versus* placebo).^[@bibr55-1758835919849753]^ Rucaparib (Rubraca^®^) was initially approved by the FDA in December 2016 for the treatment of adult patients with BRCAm (germline or somatic) epithelial ovarian cancer who have been treated with at least two prior lines of chemotherapy.^[@bibr57-1758835919849753]^ Following the results of the ARIEL3 study, in April 2018, the rucaparib FDA approval was updated as a maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.^[@bibr57-1758835919849753]^ In May 2018, rucaparib received approval in Europe for the monotherapy treatment of adult patients with PSR or progressive, BRCAm (germline or somatic), high-grade epithelial ovarian cancer, who have been treated with at least two prior lines of platinum-based chemotherapy, and are unable to tolerate further platinum-based chemotherapy.^[@bibr58-1758835919849753]^ Most recently, in January 2019, rucaparib was approved in Europe as monotherapy for the maintenance treatment of adult patients with PSR high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.

PARP inhibitors and precision medicine {#section5-1758835919849753}
======================================

The National Comprehensive Cancer Network (NCCN) clinical practice guidelines for ovarian cancer recommend olaparib or niraparib maintenance therapy after partial or complete response to platinum chemotherapy, irrespective of BRCAm testing.^[@bibr59-1758835919849753]^ These recommendations for the use of PARP inhibitors in a broad ovarian cancer indication have led to some concern of a shift away from patient-focused, personalized medicines, with a proportion of patients potentially receiving treatments that may not provide a benefit.^[@bibr60-1758835919849753]^ However, the use of mutation detection and HRD tests to direct PARP-inhibitor therapy has also caused concern, as cancers may undergo evolution in response to treatment. Indeed, in the tumours of patients with a BRCAm, reversion mutations that can restore gene function have been reported, resulting in loss of PARP-inhibitor sensitivity.^[@bibr60-1758835919849753]^ Although HRD tests help to define patients with sensitivity to PARP inhibitors, the genomic damage caused by HRD persists even if the original cause is no longer present. Therefore, tests to predict PARP-inhibitor sensitivity may become less reliable as the disease progresses^[@bibr60-1758835919849753]^ and have therefore not been widely incorporated into clinical trials. Furthermore, genomic testing has not been able to identify women who have a poor response to olaparib treatment from those who demonstrate long-term responses following olaparib treatment.^[@bibr61-1758835919849753]^ Platinum status (i.e. response to platinum-based therapy) observed in patients has outperformed novel HRD tests used in clinical studies of PARP inhibitors in patients with ovarian cancer. This may be because such HRD tests (Myriad myChoice® HRD test^[@bibr51-1758835919849753]^ used in the phase III NOVA study of niraparib,^[@bibr14-1758835919849753]^ Foundation Medicine FoundationFocus^TM^ CDx~BRCA\ LOH~ assay^[@bibr56-1758835919849753]^ used in the phase III ARIEL3 study of rucaparib^[@bibr55-1758835919849753]^ and HRD evaluation used in the phase II Study 19 of olaparib)^[@bibr62-1758835919849753]^ do not investigate currently unknown genes that are involved in HRR.^[@bibr63-1758835919849753]^ Platinum sensitivity therefore remains an important determinant of PARP-inhibitor sensitivity.

Another concern of the broad labels for PARP inhibitors in the treatment of ovarian cancer is the risk that physicians will not perform BRCA testing. Assessing for a BRCAm not only identifies patients who are most likely to respond to treatment with PARP inhibitors and platinum agents but also identifies patients with a germline BRCAm, which enables their relatives to be informed and undergo testing and risk-reduction treatments if required.

Treatment decision making for patients with platinum-sensitive relapsed ovarian cancer {#section6-1758835919849753}
======================================================================================

PARP inhibitors have provided PSR ovarian cancer patients in response to their most recent platinum-based regimen with a new maintenance treatment option that has been shown to extend PFS and therefore delay the requirement for additional lines of platinum-based chemotherapy. New definitions of platinum sensitivity based on response to platinum, rather than platinum-free interval of ⩾6 months from prior therapy, may influence clinical decision making for selecting patients for maintenance therapy with a PARP inhibitor.^[@bibr64-1758835919849753]^ PARP inhibitors are shown to be well tolerated and maintain patient QoL. Olaparib, niraparib and rucaparib have all demonstrated a significant benefit as maintenance therapies for patients with PSR ovarian cancer. The unprecedented maintenance treatment with olaparib in PSR ovarian cancer patients for at least 6 years, with long-term tolerability and efficacy, demonstrates that this treatment has the potential to enable patients to be in long-term remission of their disease.

Second-line maintenance treatment options for patients with PSR ovarian cancer also include treatment with the antiangiogenic monoclonal antibody bevacizumab,^[@bibr65-1758835919849753],[@bibr66-1758835919849753]^ and therefore treatment algorithms are required ([Figure 4](#fig4-1758835919849753){ref-type="fig"}). For example, it may be favourable to consider bevacizumab in patients with malignant ascites, as it has been reported to improve control of ascites,^69^ and in patients with symptomatic relapse, particularly with effusions where rapid control of disease is needed. However, for all other patients with PSR ovarian cancer who are in response (complete or partial) to their second-line platinum-based chemo-therapy regimen, treatment with a PARP inhibitor should be initiated regardless of their BRCAm status. PARP-inhibitor treatment is not only convenient for patients, being an oral treatment, but has demonstrated long-term survival benefit, which has not been shown with bevacizumab.^[@bibr30-1758835919849753],[@bibr67-1758835919849753]^

![Treatment algorithm for patients with platinum-sensitive relapsed ovarian cancer.\
^\*^There are limited data on the efficacy of bevacizumab in the recurrence therapy setting for patients with platinum-sensitive disease previously treated with bevacizumab.\
PARP, poly (ADP-ribose) polymerase inhibitor.](10.1177_1758835919849753-fig4){#fig4-1758835919849753}

There is now a choice of PARP inhibitors available for PSR ovarian cancer patients as maintenance therapy following platinum-based treatment. For olaparib, the dosing and bioavailability of tablets and capsules is different, and the two formulations should not be used interchangeably; if the capsule posology is used for the tablets, there is a risk of overdose and increased adverse events, and if the tablet posology is used for the capsules, there is a risk of lack of efficacy. Healthcare professionals should inform patients that olaparib capsules and tablets are not interchangeable and refer patients to the information provided in the package leaflet. There is no guidance about the choice of drug. The side-effect profiles are similar, although there are differences between the drugs. No comparative activity data exist, and selection is often based on familiarity with the drug and its availability.

Rechallenge with PARP-inhibitor maintenance treatment after relapse and subsequent platinum-based chemotherapy may be a viable treatment option and is currently under investigation \[(OReO) ClinicalTrials.gov identifier: NCT03106987 (olaparib retreatment in patients with or without a BRCAm)\], as is PARP-inhibitor combination treatment with other targeted agents including immuno-oncology drugs. The results of these trials will provide further direction of the treatment approach for patients with PSR ovarian cancer.

Conclusion {#section7-1758835919849753}
==========

In summary, PARP inhibitors were developed with the intention of treating patients with HRD, specifically for patients with tumours that harbour a BRCAm. Evidence from clinical trials to date has demonstrated that patients with a BRCAm derive the greatest benefit from PARP inhibitors. However, there is a clear body of evidence showing that PARP inhibitors also benefit ovarian cancer patients without a BRCAm and the approval of olaparib, niraparib and rucaparib by the FDA and EMA in all PSR ovarian cancer populations who are in response to platinum supports this. Long-term tolerability and efficacy of olaparib have been demonstrated in patients both with and without a BRCAm through Study 19, with patients receiving maintenance treatment for 6 years or more, which is unprecedented in the relapsed ovarian-cancer setting. Further studies should be performed to elucidate which non-BRCAm patients are deriving benefit, and what HRD molecular processes are enabling this, so that patients continue to receive optimal treatment for their disease.
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